---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095687"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:35:40.630044+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics Q2 revenue down 14% to $25.2M, net income up to $4.5M; receives NMPA approval for avatrombopag

## Summary
- Q2 revenue $25.2M (-14% YoY) on normalized ETUARY sales; net income $4.5M vs $3.8M YoY.
- H1 revenue $52.4M (-3.5% YoY); net income $14.5M vs $8.0M YoY, driven by lower costs.
- Received NMPA approval for avatrombopag for CLD thrombocytopenia (July 2024); expanded rare disease portfolio.
- IND approved for F230 in PAH; Phase 3 F351 CHB data expected early 2025; U.S. IND for F351 in MASH by end 2024.
- Appointed David M. Epstein to Board; cash and investments ~$54M, sufficient for 12+ months.

## SEC filing metadata
- accession: 0000950170-24-095687
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000095017024095687/0000950170-24-095687-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000095017024095687/gyre-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095687
- JSON: https://secwatch.observer/filing/0000950170-24-095687.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095687.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.